Unresectable Triple-Negative Breast Carcinoma Clinical Trials

11 clinical trials for Unresectable Triple-Negative Breast Carcinoma across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer — RECRUITING · PHASE1
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer — RECRUITING · PHASE1
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer — RECRUITING · PHASE2
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer — RECRUITING · PHASE1
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer — SUSPENDED · PHASE1
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE2
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer — WITHDRAWN · PHASE1
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer — TERMINATED · PHASE1
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer — WITHDRAWN · PHASE2

Refine this search